Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

 


PROSPECTUS SUMMARY

        This summary highlights information contained in greater detail elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider in making your investment decision. You should read the entire prospectus carefully before making an investment in our common stock. You should carefully consider, among other things, our financial statements and the related notes and the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus.


Overview

Our Company

        We are a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases that represent large market opportunities where there are significant unmet medical needs. We are developing a robust and growing portfolio of novel product candidates generated by Contour®, our proprietary structure-based drug discovery platform. Our team of accomplished scientists utilizes Contour to rapidly discover highly potent and selective product candidates for validated but difficult-to-drug targets in multiple disease areas. Our most advanced product candidates include VTP-34072, which is expected to commence a Phase 2 clinical trial for the treatment of type 2 diabetes in July 2014, with data expected in the first half of 2015, and VTP-37948, which is in Phase 1 clinical trials for the treatment of Alzheimer's disease, or Alzheimer's, with data expected in the second half of 2014. Both product candidates are being exclusively developed and following regulatory approval, if any, commercialized by Boehringer Ingelheim GmbH, or BI, under separate collaborations. These collaborations have provided us with an aggregate of $152.4 million in funding to date, including upfront license fees, research funding and success-based milestone payments as well as equity investments. In addition, we have several wholly-owned product candidates advancing in preclinical studies, including: VTP-43742 for the treatment of autoimmune disorders, where the immune system attacks normal tissues, with Phase 1 proof-of-concept data, which is the demonstration of therapeutic activity, expected by the end of 2015; VTP-38443 for the treatment of acute coronary syndrome, which includes unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. However, we currently do not hold any active authorizations to conduct clinical trials with respect to any of our wholly-owned product candidates and, at this time, we rely on BI for the conduct of clinical trials for our two partnered product candidates.

Our Contour Technology Platform

        We believe we are a leader in the field of structure-based drug discovery, which is the use of computers to design drugs utilizing detailed target protein structures as the guide for design, and have leveraged our expertise to create a growing portfolio of novel, potent and selective product candidates. We utilize Contour to discover and develop product candidates for validated therapeutic targets, which are the proteins through which a drug mediates activity, against which the industry has traditionally struggled to develop drugs due to challenges related to potency, selectivity, pharmacokinetics, or the change in drug levels over time, or patentability issues. We refer to these targets as "difficult-to-drug." Contour's computational software uses artificial intelligence and sophisticated algorithms to model the assembly of molecular fragments into fully elaborated, drug-like structures that precisely fit each target's 3-dimensional binding site. These molecules are then assessed by Contour's state-of-the-art scoring function, which is a computer program that predicts how tightly a drug will bind to its active site, to identify the most promising and drug-like structures. Together, these functions allow us to rapidly focus on those structures with the highest potential from among hundreds of billions of possibilities for a given biologic target. We chemically synthesize, comprehensively test, and critically evaluate and modify these novel structures until we identify product candidates with demonstrable first- or best-in-class potential. Our scientists utilize our platform and approach to develop each of our product candidates to rapidly overcome discovery obstacles. We have

 

1